Tekmira and Bristol-Myers in validation program
May 10, 2010 by stephenkilmer · Leave a Comment
Tekmira Pharmaceuticals (TSX:TKM) has signed a four-year agreement with Bristol-Myers Squibb (NYSE:BMY) to validate certain cellular targets using its stable nucleic acid-lipid particles (SNALP) technology in exchange for an upfront payment of $3 million (U.S.). Under the agreement, Bristol-Myers Squibb will use RNA interfering molecules formulated by Tekmira in SNALP to silence target genes of [...]
Listen to BioTuesdays 
